Elvan Alper Sengul

Prof. Dr. Elvan Alper Sengul


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in Current Eye Research
Verified
Journal Article
Closed access
EYErdal Yuzbasioglu
Erdal Yuzbasioglu
OAOzgur Artunay
Ozgur Artunay
RRRifat Rasier
Rifat Rasier
ESElvan Alper Sengul
Elvan Alper Sengul
HBHalil Bahcecioglu
Halil Bahcecioglu
Purpose: To evaluate and report the effectiveness, visual, anatomical, and clinical outcome of intravitreal bevacizumab (Avastin) injection in patients with retinitis pigmentosa (RP). Methods: Our prospective study included 13 eyes of 7 patients (4 women and 3 men) in the age range of 25–69 years (mean 44.14 years) with cystoid macular edema (CME) secondary to RP. Intravitreal bevacizumab at a dose of 1.25 mg/0.05 ml was injected via a 28-gauge needle. The response rate to treatment was monitored functionally by visual acuity assessment and anatomically using the optical coherence tomography. Results: The baseline mean central macular thickness was 370.15 μ m (range 245–603 μ m. The central macular thickness decreased to 142.53 μ m (range 124–168 μ m) after bevacizumab injections. The pre- and post-treatment visual acuity ranges were 5/400–20/100 and 20/200–20/63, respectively. Conclusions: Our data reveal that intravitreal bevacizumab administration is effective for the treatment of CME in RP. Further studies with a larger population and longer follow-up period are warranted to assess the efficacy of the treatment.

12 May 2017 in International Journal of Ophthalmology
Verified
Journal Article
Open access
ESElvan Alper Sengul
Elvan Alper Sengul
OAOzgur Artunay
Ozgur Artunay
AKAlev Kockar
Alev Kockar
CACeyda Afacan
Ceyda Afacan
RRRifat Rasier
Rifat Rasier
EYErdal Yuzbasioglu
Erdal Yuzbasioglu
To investigate the place of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in the diagnosis of and prognosis for neovascular age-related macular degeneration (AMD). One hundred AMD patients and 100 healthy controls were included in the study. Blood samples were obtained from the venous blood, which is used for routine analysis, and these samples were subjected to complete blood count. NLR was defined as the neutrophil count divided by the number of lymphocytes, and PLR was defined as the platelet count divided by the number of lymphocytes. No statistically significant difference was observed between the two groups under consideration in terms of demographic features (P>0.05). The average NLR in the patient group was found to be significantly higher than that in the healthy control group (P<0.05). The average PLR was significantly higher in the patient group as compared to the control group (P<0.05). As best corrected visual acuity (BCVA) increased, both NLR and PLR decreased (significant negative correlations at 49.8% and 63.0%, respectively), whereas as central macular thickness (CMT) increased, both NLR and PLR increased (significant positive correlations at 59.3% and 70.0%, respectively). NLR and PLR levels are higher among neovascular AMD patients as compared to healthy control group. NLR and PLR levels were found to be inversely proportional to BCVA and directly proportional to CMT.

1 June 2010 in Journal of Ocular Pharmacology and Therapeutics
Verified
Journal Article
Closed access
OAOzgur Artunay
Ozgur Artunay
EYErdal Yuzbasioglu
Erdal Yuzbasioglu
RRRifat Rasier
Rifat Rasier
ESElvan Alper Sengul
Elvan Alper Sengul
HBHalil Bahcecioglu
Halil Bahcecioglu
The posterior reversible encephalopathy syndrome (PRES), a complex of cerebral disorders including headache, seizures, visual disturbances, is associated with a variety of conditions in which blood pressure rises acutely. Arterial hypertension can occur in systemic administration of bevacizumab. A few cases of systemic injection of bevazicumab-induced PRES have been reported. In this article, we first report on a patient who developed PRES following intravitreal bevazicumab.

18 November 2016 in Journal of Ocular Pharmacology and Therapeutics
Verified
Journal Article
Closed access
ESElvan Alper Sengul
Elvan Alper Sengul
OAOzgur Artunay
Ozgur Artunay
EKEsra Turkseven Kumral
Esra Turkseven Kumral
MYMelda Yenerel
Melda Yenerel
RRRifat Rasier
Rifat Rasier
EYErdal Yuzbasioglu
Erdal Yuzbasioglu
Purpose: The objective of this study was to investigate the effect of multiple intravitreal ranibizumab (IVR) injections on the retinal nerve fiber layer (RNFL) in neovascular age-related macular degeneration (nAMD). Methods: One hundred sixty-eight eyes of 168 patients with nAMD who received an IVR at least 3 times were included in this prospective interventional case series. The RNFL thickness data on 80 healthy eyes, used as the control group, were obtained. The patients were grouped as follows: 3–10 injections (group 1, 62 eyes, 37%), 10–20 injections (group 2, 62 eyes, 37%), and ≥20 injections (group 3, 44 eyes, 26%). The RNFL thickness was measured by spectral domain optical coherence tomography. Results: The mean baseline measurement of the RNFL thickness was 97.4 ± 6.4 μm in the control group, 96.4 ± 5.6 μm in group 1, 93.8 ± 4.6 μm in group 2, and 93.2 ± 5.3 μm in group 3. At the last follow-up, it was 95.1 ± 2.4 μm in the control group, 93.4 ± 7.3 μm in group 1, 90.5 ± 3.6 μm in group 2, and 89.2 ± 4.9 μm in group 3 (all P values >0.050). A statistically significant difference was not found between the mean total RNFL thickness of the eyes that received injections and that of the eyes in the healthy control group ( P value >0.050). A statistically significant difference was not found in all the treatment groups between the intraocular pressure level taken 1 day after the administration of the injections and that recorded preintervention (all P values >0.050). Conclusion: Repeated IVR did not lead to a significant change in RNFL thickness in patients with nAMD.

5 August 2021 in Korean Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
OUOzgul Ugurtay
Ozgul Ugurtay
AKAlev Kockar
Alev Kockar
ESElvan Alper Sengul
Elvan Alper Sengul
To compare functional and anatomic outcome of intravitreal ranibizumab (IVR) and intravitreal aflibercept (IVA) treatments in neovascular age related macular degeneration (nAMD) by using the treat an extend (TE) protocol. In this retrospective chart study, treatment naïve 74 eyes of 74 nAMD patients treated with IVR and IVA (38 eyes in IVR and 36 eyes in IVA group) with TE protocol were included. Following three consecutive monthly intravitreal injections, TE protocol was applied to each group. Patients were followed up for at least 36 months. Mean change in best corrected visual acuity (BCVA), central macula thickness (CMT) and injection numbers over 3 years were compared. Among 36 months period, the mean number of injection was 17±4 for both groups (p>0.05). In terms of CMT, there was no statistically significant difference between groups at 36 months compared to baseline. A decrease of 72.55±39.37 μm in CMT was detected in IVR group, whereas the decrease was 70.58±33.96 μm in IVA group (p>0.05). There was a significant increase in BCVA at 36 months of measurements. In addition, BCVA demonstrated an increase of 4.1±0.44 letters in IVR group and 4.36±0.67 letters in IVA group after 36 months compared to the baseline (p>0.05). Both IVR and IVA injections provided significant improvements and stability in BCVA and CMT, however there was no significant difference between IVR and IVA injections with TE protocol of 36 months.

4 May 2017 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
ESElvan Alper Sengul
Elvan Alper Sengul
OAOzgur Artunay
Ozgur Artunay
RRRifat Rasier
Rifat Rasier
AKAlev Kockar
Alev Kockar
CACeyda Afacan
Ceyda Afacan
EYErdal Yuzbasioglu
Erdal Yuzbasioglu
Purpose: This study aims to evaluate the role of complement factor H (CFH) in response to intravitreal ranibizumab (IVR) treatment, which is administered to patients with neovascular age-related macular degeneration (nAMD). Methods: In this retrospective study, 90 nAMD patients’ 90 eyes were evaluated. IVR was injected once a month for three consecutive months, and then, patients were followed up for five years by using pro re nata method. Results: Average visual acuity (BCVA) values in TT group for the third, fourth and fifth years were found to be significantly higher than those in TC and CC groups, while average BCVA values in TC group were significantly higher than those in CC group (all p = .000 < .0167). Conclusion: Patients with CFH TT genotype responded significantly better to treatment after third year, while patients with CC genotype had a poorer response to IVR.